Bryce Chiang, MD
Ophthalmology · Baltimore
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 6
Offices
6 locations · Johns Hopkins University · 2,886 clinicians in this group
Hospitals listed: Johns Hopkins Hospital, the. That is not proof they admit you there this week.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chiang’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A165900 · Current
Licensed to practise in California · since 2019 · expires 2027-10-31 · Emory University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Johns Hopkins Hospital, theBaltimore, MDAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Johns Hopkins Health System, which runs 6 hospitals in 3 statesHome of Sidney Kimmel Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.84 (1.19 to 2.49) · 4,951 cases, Jul 2022 – Jun 2024Worse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.17 (1.01 to 1.32), Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.3 (11.7 to 15.1) · 1,609 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.605, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.358, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.302, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 4 (3.2 to 5) · 1,609 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Johns Hopkins Hospital, the
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 4 better, 2 the same, 1 worse of 7 measures. Readmissions: 1 better, 6 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.84 (1.19 to 2.49) · 4,951 cases | Worse | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.17 (1.01 to 1.32) | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.3 (11.7 to 15.1) · 1,609 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.605 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.358 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.302 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (3.2 to 5) · 1,609 cases | Better | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 160.59 (131.83 to 189.35) · 409 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.4 · 266 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.7 · 173 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.8 · 563 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 8.9 · 377 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.1 · 283 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.5 · 4,532 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.36 (0.2 to 0.51) · 17,508 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.14 to 0.45) · 19,518 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (3.36 to 5.72) · 6,562 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.87 (1 to 2.74) · 4,318 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.32 (1.41 to 3.23) · 5,830 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.82 (7.25 to 12.39) · 4,056 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.01 (3.33 to 6.69) · 4,266 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.42 (0.26 to 2.59) · 2,087 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.85 (0.52 to 1.18) · 17,435 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.819 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.654 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.829 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.4 · 182 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.9 · 682 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.6 · 189 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -15.5 · 647 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 45.6 · 396 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 406 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.6 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 245 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,351 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,483 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,167 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 80% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$34,059
Medicare paid this office $34,059 for 85 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 40 | $4,957 | $103 |
| New patient visit (45+ min) | 26 | $3,392 | $130 |
| Exam of visual field with extended testing | 50 | $2,474 | $49 |
| Imaging of optic nerve | 44 | $1,160 | $26 |
| Exam of the internal drainage system of eye | 40 | $903 | $23 |
See all 6 services
| Return visit (30+ min) | 40 | $4,957 | $103 |
| New patient visit (45+ min) | 26 | $3,392 | $130 |
| Exam of visual field with extended testing | 50 | $2,474 | $49 |
| Imaging of optic nerve | 44 | $1,160 | $26 |
| Exam of the internal drainage system of eye | 40 | $903 | $23 |
| Ultrasound scan of cornea to determine thickness | 31 | $275 | $9 |
Procedures Medicare counted
| Cataract surgery | 65 | More than 68% of doctors who do this |
Who their Medicare patients are
85 Original Medicare patients in 2024. Average age 73 · Under 65 14% · 85 and older 15% · Women 56% · Also on Medicaid 44% · Health risk score 1.38. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 46% · Coronary heart disease 27% · Chronic kidney disease 24% · Depression 21% · COPD 18% · Heart failure 15% · Stroke 15%.
The office billed $170,509, Medicare allowed $43,297 and paid $34,059; for 304 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 85 | 304 | 73 | 1.38 | $170,509 | $34,059 |
| 2023 | 59 | 82 | 76 | 1.78 | $74,769 | $5,902 |
| 2022 | 34 | 40 | 74 | 1.39 | $22,161 | $2,728 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 16 | $1,589 | $88 |
| Short return visit (20+ min) | 25 | $1,371 | $55 |
2022: 1 service
| Short return visit (20+ min) | 22 | $1,200 | $55 |
Medicaid work
$225 in 2023
Medicaid paid $225 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 12 | $225 |
| 2023 | 12 | 1 | 12 | $225 |
Drugs they prescribed that Part D paid
$215,402
Pharmacies billed $215,402 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,802) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
978 generic and 824 brand-name prescriptions · $215,402 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rhopressa | 56 | $28,196 | $503 |
| Lumigan | 58 | $25,619 | $442 |
| Combigan | 32 | $13,382 | $418 |
| Vyzulta | 24 | $12,497 | $521 |
| Alphagan P | 13 | $11,649 | $896 |
See all 24 drugs
| Rhopressa | 56 | $28,196 | $503 |
| Lumigan | 58 | $25,619 | $442 |
| Combigan | 32 | $13,382 | $418 |
| Vyzulta | 24 | $12,497 | $521 |
| Alphagan P | 13 | $11,649 | $896 |
| Azopt | 17 | $10,172 | $598 |
| Brimonidine | 121 | $9,460 | $78 |
| Rocklatan | 23 | $9,165 | $398 |
| Brinzolamide | 36 | $8,982 | $250 |
| Simbrinza | 23 | $8,971 | $390 |
| Timolol Maleate | 17 | $8,719 | $513 |
| Travoprost | 36 | $8,696 | $242 |
| Restasis | 14 | $7,633 | $545 |
| Zioptan | 17 | $5,879 | $346 |
| Timolol Maleate | 264 | $5,720 | $22 |
| Latanoprost | 593 | $5,490 | $9 |
| Dorzolamide-Timolol | 27 | $4,094 | $152 |
| Brimonidine Tartrate-Timolol | 24 | $2,708 | $113 |
| Prednisolone Acetate | 55 | $2,424 | $44 |
| Tafluprost | 16 | $2,318 | $145 |
| Dorzolamide-Timolol | 132 | $2,145 | $16 |
| Dorzolamide | 74 | $1,502 | $20 |
| Pilocarpine | 16 | $724 | $45 |
| Moxifloxacin | 25 | $638 | $26 |
Year by year
| 2024 | 1,802 | 532 | 0% (0) | 46% | $215,402 |
| 2023 | 2,274 | 713 | 0% (0) | 50% | $372,077 |
| 2022 | 327 | 148 | 0% (0) | 50% | $45,487 |
| 2021 | 69 | 19 | 0% (0) | 55% | $9,717 |
| 2020 | 39 | 15 | 0% (0) | 59% | $6,793 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Restasis | 50 | $39,820 | $796 |
| Lumigan | 73 | $38,879 | $533 |
| Rhopressa | 71 | $36,803 | $518 |
| Brinzolamide | 51 | $21,893 | $429 |
| Simbrinza | 52 | $20,324 | $391 |
| Alphagan P | 36 | $20,185 | $561 |
| Travoprost | 63 | $14,830 | $235 |
| Timolol Maleate | 21 | $13,968 | $665 |
| Brimonidine | 182 | $13,687 | $75 |
| Xiidra | 11 | $13,585 | $1,235 |
| Combigan | 30 | $13,203 | $440 |
| Rocklatan | 19 | $11,861 | $624 |
| Latanoprost | 661 | $11,209 | $17 |
| Tafluprost | 40 | $10,835 | $271 |
| Vyzulta | 20 | $10,206 | $510 |
| Travatan Z | 13 | $8,877 | $683 |
| Azopt | 15 | $8,557 | $570 |
| Dorzolamide-Timolol | 53 | $7,588 | $143 |
| Zioptan | 17 | $6,831 | $402 |
| Prednisolone Acetate | 120 | $6,719 | $56 |
| Dorzolamide-Timolol | 176 | $6,282 | $36 |
| Brimonidine Tartrate-Timolol | 14 | $3,920 | $280 |
| Timolol Maleate | 192 | $3,914 | $20 |
| Cosopt Pf | 11 | $3,440 | $313 |
| Difluprednate | 22 | $2,756 | $125 |
| Dorzolamide | 88 | $2,608 | $30 |
| Methazolamide | 11 | $1,988 | $181 |
| Acetazolamide | 15 | $1,087 | $72 |
| Ketorolac Tromethamine | 17 | $852 | $50 |
| Moxifloxacin | 24 | $614 | $26 |
| Olopatadine | 18 | $509 | $28 |
| Erythromycin | 13 | $176 | $14 |
2022: 11 drugs
| Rhopressa | 16 | $8,450 | $528 |
| Zioptan | 11 | $3,419 | $311 |
| Travoprost | 11 | $3,381 | $307 |
| Prednisolone Acetate | 30 | $1,859 | $62 |
| Latanoprost | 84 | $1,765 | $21 |
| Brimonidine | 14 | $1,592 | $114 |
| Ketorolac Tromethamine | 13 | $566 | $44 |
| Dorzolamide-Timolol | 17 | $541 | $32 |
| Dorzolamide | 20 | $421 | $21 |
| Moxifloxacin | 12 | $368 | $31 |
| Timolol Maleate | 20 | $332 | $17 |
2021: 2 drugs
| Doxycycline Hyclate | 11 | $322 | $29 |
| Latanoprost | 15 | $265 | $18 |
Money from drug and device companies
$87 in 2025
| 2025 | 1 | 1 | None | $87 |
| 2024 | 4 | 5 | None | $151 |
| 2023 | 4 | 4 | None | $245 |
| 2022 | 4 | 18 | None | $707 |
| 2021 | 2 | 12 | None | $428 |
| 2019 | 1 | 1 | None | $117 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Hydrus Microstent | $87 | 1 payment
|
See the published payment
| Alcon Vision | Meals · 2025-02-28 | Hydrus Microstent | $87 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $151
| Alcon Vision | Hydrus Microstent | $84 | 2 payments
|
| Johnson & Johnson Surgical Vision | Tecnis Simplicity | $24 | 1 payment
|
| Abbvie | Durysta | $23 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $19 | 1 payment
|
2023: $245
| AbbVie | Durysta | $83 | 1 payment
|
| Nova Eye | None | $66 | 1 payment
|
| Alcon Vision | Hydrus Microstent | $64 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $33 | 1 payment
|
2022: $707
| Alcon Vision | Acrysof Iq Panoptix Uv Iol | $409 | 13 payments
|
| Sight Sciences | Omni(R) Surgical System (US) | $192 | 3 payments
|
| Glaukos | Istent Inject W | $86 | 1 payment
|
| Bausch & Lomb Americas | Prolensa | $19 | 1 payment
|
2021: $428
| Alcon Vision | Acrysof Iq Panoptix | $401 | 11 payments
|
| Bausch & Lomb a division of Bausch Health US | Prolensa | $27 | 1 payment
|
2019: $117
| Aerie Pharmaceuticals | Rhopressa | $117 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1053816462
- Licence
- CA A165900California A165900: Current · expires 2027-10-31
- Trained
- Emory University School of Medicine, 2018
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 6201 Greenleigh Ave Fl 2, Middle River, MD, 21220
- NPI first listed
- 2018-03-27
- NPI last updated
- 2024-11-20
- NPI record certified
- 2024-11-20
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305